Overview

A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease

Status:
Active, not recruiting

Trial end date:
2024-08-29

Target enrollment:

Participant gender:

Summary

This study will be conducted to evaluate the efficacy of lecanemab in participants with early Alzheimer's disease (EAD) by determining the superiority of lecanemab compared with placebo on the change from baseline in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) at 18 months of treatment in the Core Study. This study will also evaluate the long-term safety and tolerability of lecanemab in participants with EAD in the Extension Phase and whether the long-term effects of lecanemab as measured by the CDR-SB at the end of the Core Study is maintained over time in the Extension Phase.

Phase:

Phase 3

Details

Lead Sponsor:

Eisai Inc.

Collaborator:

Biogen